^
Association details:
Biomarker:MAP2K1 K57T
Cancer:Colon Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer

Excerpt:
We report the emergence of the novel MEK1V211D gatekeeper mutation in a patient with BRAFK601E colon cancer treated with the allosteric MEK inhibitor binimetinib and the anti-EGFR antibody panitumumab...The V211D mutation causes resistance to binimetinib by both increasing the catalytic activity of MEK1 and reducing its affinity for the drug.
DOI:
10.1158/2159-8290.CD-19-0356